STAAR Surgical vs Lantheus: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

STAAR Surgical Company (STAA)

Q3 202617 Jul – 24 Sep 2026

▲2▼2

STAAR's China boom and buyback lift it, but guidance silence and insurance fears weigh

No second-half guidance spooks investors STAAR beat second-quarter sales estimates, yet management gave no guidance for the rest of the year and stayed cautious. Analysts said investors want that clarity before buying, and the stock fell about 10% — the drop is about uncertainty, not weak sales.
Explains the sharp negative reaction despite a sales beat, a key force behind the stock's move.
Insurance changes threaten US procedure volumes Intuitive Surgical warned that changes to some insurance plans could slow US procedures, dragging medical device stocks down together. Fewer covered procedures means fewer people getting STAAR's lens implants, so the whole sector — including STAAR — sold off on demand worries.
Shows an industry-wide demand headwind that pushed STAA down alongside peers.
China sales more than double, swinging STAAR to profit STAAR posted $8.1 million net income versus a year-earlier loss, with sales up 111% to $93.5 million. China revenue more than doubled to $52.3 million on the new EVO+ lens, lifting volumes and prices. Management cautioned the growth compares against an unusually weak prior year.
The core fundamental driver: real profit and booming China demand that support the stock.
$50M buyback signals confidence and supports the stock STAAR's board approved buying back up to $50 million of stock over 12 months, roughly 5% of shares, funded from cash and free cash flow. With no debt and $181.5 million in cash, this returns money to shareholders and can lift the share price.
A concrete capital action that directly supports STAA's share price.

August 202617 Jul – 24 Sep 2026

▲2▼2

STAAR's China boom and buyback lift it, but guidance silence and insurance fears weigh

No second-half guidance spooks investors STAAR beat second-quarter sales estimates, yet management gave no guidance for the rest of the year and stayed cautious. Analysts said investors want that clarity before buying, and the stock fell about 10% — the drop is about uncertainty, not weak sales.
Explains the sharp negative reaction despite a sales beat, a key force behind the stock's move.
Insurance changes threaten US procedure volumes Intuitive Surgical warned that changes to some insurance plans could slow US procedures, dragging medical device stocks down together. Fewer covered procedures means fewer people getting STAAR's lens implants, so the whole sector — including STAAR — sold off on demand worries.
Shows an industry-wide demand headwind that pushed STAA down alongside peers.
China sales more than double, swinging STAAR to profit STAAR posted $8.1 million net income versus a year-earlier loss, with sales up 111% to $93.5 million. China revenue more than doubled to $52.3 million on the new EVO+ lens, lifting volumes and prices. Management cautioned the growth compares against an unusually weak prior year.
The core fundamental driver: real profit and booming China demand that support the stock.
$50M buyback signals confidence and supports the stock STAAR's board approved buying back up to $50 million of stock over 12 months, roughly 5% of shares, funded from cash and free cash flow. With no debt and $181.5 million in cash, this returns money to shareholders and can lift the share price.
A concrete capital action that directly supports STAA's share price.

Latest17 Jul – 24 Sep 2026

▲2▼2

STAAR's China boom and buyback lift it, but guidance silence and insurance fears weigh

No second-half guidance spooks investors STAAR beat second-quarter sales estimates, yet management gave no guidance for the rest of the year and stayed cautious. Analysts said investors want that clarity before buying, and the stock fell about 10% — the drop is about uncertainty, not weak sales.
Explains the sharp negative reaction despite a sales beat, a key force behind the stock's move.
Insurance changes threaten US procedure volumes Intuitive Surgical warned that changes to some insurance plans could slow US procedures, dragging medical device stocks down together. Fewer covered procedures means fewer people getting STAAR's lens implants, so the whole sector — including STAAR — sold off on demand worries.
Shows an industry-wide demand headwind that pushed STAA down alongside peers.
China sales more than double, swinging STAAR to profit STAAR posted $8.1 million net income versus a year-earlier loss, with sales up 111% to $93.5 million. China revenue more than doubled to $52.3 million on the new EVO+ lens, lifting volumes and prices. Management cautioned the growth compares against an unusually weak prior year.
The core fundamental driver: real profit and booming China demand that support the stock.
$50M buyback signals confidence and supports the stock STAAR's board approved buying back up to $50 million of stock over 12 months, roughly 5% of shares, funded from cash and free cash flow. With no debt and $181.5 million in cash, this returns money to shareholders and can lift the share price.
A concrete capital action that directly supports STAA's share price.

Lantheus Holdings Inc (LNTH)

Q3 202626 Jun – 14 Aug 2026

▲2▼1

Curium's $8B buyout and new FDA approval reshape Lantheus

Curium agrees to acquire Lantheus for up to $8 billion Curium will pay $102.50 per share in cash plus up to $12 more if sales targets are met, a 14.9% premium. This puts a firm floor under the stock and is the main reason it trades near the offer price.
The buyout is the single biggest force driving LNTH's price and future value.
FDA approves Tauklarify for tau PET imaging The FDA approved Tauklarify, a new imaging agent for Alzheimer's tau pathology. This adds a new product to Lantheus's portfolio and could support the contingent value rights tied to future sales.
A new FDA approval is a fresh positive catalyst that can affect the buyout's contingent payments.
FDA rejects LNTH-2501 due to third-party facility issues The FDA issued a Complete Response Letter for LNTH-2501, a PET diagnostic for neuroendocrine tumors, because of unresolved manufacturing issues at a partner's facility. This delays a potential product but does not question the drug's data.
This is a fresh regulatory setback that could weigh on sentiment and future growth prospects.

July 202626 Jun – 14 Aug 2026

▲2▼1

Curium's $8B buyout and new FDA approval reshape Lantheus

Curium agrees to acquire Lantheus for up to $8 billion Curium will pay $102.50 per share in cash plus up to $12 more if sales targets are met, a 14.9% premium. This puts a firm floor under the stock and is the main reason it trades near the offer price.
The buyout is the single biggest force driving LNTH's price and future value.
FDA approves Tauklarify for tau PET imaging The FDA approved Tauklarify, a new imaging agent for Alzheimer's tau pathology. This adds a new product to Lantheus's portfolio and could support the contingent value rights tied to future sales.
A new FDA approval is a fresh positive catalyst that can affect the buyout's contingent payments.
FDA rejects LNTH-2501 due to third-party facility issues The FDA issued a Complete Response Letter for LNTH-2501, a PET diagnostic for neuroendocrine tumors, because of unresolved manufacturing issues at a partner's facility. This delays a potential product but does not question the drug's data.
This is a fresh regulatory setback that could weigh on sentiment and future growth prospects.

Latest26 Jun – 14 Aug 2026

▲2▼1

Curium's $8B buyout and new FDA approval reshape Lantheus

Curium agrees to acquire Lantheus for up to $8 billion Curium will pay $102.50 per share in cash plus up to $12 more if sales targets are met, a 14.9% premium. This puts a firm floor under the stock and is the main reason it trades near the offer price.
The buyout is the single biggest force driving LNTH's price and future value.
FDA approves Tauklarify for tau PET imaging The FDA approved Tauklarify, a new imaging agent for Alzheimer's tau pathology. This adds a new product to Lantheus's portfolio and could support the contingent value rights tied to future sales.
A new FDA approval is a fresh positive catalyst that can affect the buyout's contingent payments.
FDA rejects LNTH-2501 due to third-party facility issues The FDA issued a Complete Response Letter for LNTH-2501, a PET diagnostic for neuroendocrine tumors, because of unresolved manufacturing issues at a partner's facility. This delays a potential product but does not question the drug's data.
This is a fresh regulatory setback that could weigh on sentiment and future growth prospects.